ITM Isotope Technologies Munich SE

Name ›

IRBM S.p.A

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Via Pontina Km 30,600 00071 Pomezia (Rome) Italy Heidi Kingdon Jones +39-06-91093-692 +39-06-91093-654 bd@irbm.com / h.kingdon@irbm.com https://www.irbm.com/

I

200 2009 | Chemistry | Biology | NMR | Animal facility | Analytics | Prep lab (Kg-scale, non GMP) | BSL 1, 2, 2+

Integrated drug discovery | Display technologies | Antibody discovery | Peptide drug discovery | Small molecule drug discovery | Biomarker identification and development | Discovery and translational biology | High-content and high-throughput biology and screening | ADME/DMPK | In vivo pharmacology | Structural biology and virtual screening

| Antios Therapeutics | MSD | MD Anderson Cancer Center | AstraZeneca (with IRBM’s Advent) | CHDI

Areas of Activity ›

External ›

Collaborations

European Biotechnology

Ex-Big Pharma drug hunters

IRBM is a former MSD site operating as an innovative contract research organisation working across all aspects of drug discovery and early development for different modalities – small molecules, peptides and antibodies.

Excellent drug discovery track record

Scientific excellence is in our DNA. Our team has invented and worked on 4 marketed drugs: ISENTRESS® (a first-in-class HIV integrase inhibitor), ZOLINZA® (the first HDAC inhibitor for non-small cell lung cancer), Grazoprevir (ZEPATIER® for HCV), and ZEJULA® (a PARP inhibitor for ovarian cancer). We have delivered over 25 preclinical candidates, and published an unprecedented number of papers.

Customised solutions for each project

Based on our experience, IRBM offers tailored solutions to clients and contributes know-how as well as critical assessment of the results. As many of the studies are exploratory by nature, IRBM often uses its strong scientific foundation to develop completely novel methods and experimental set-ups. Through our scientific expertise, providing insights and the highest quality standards, we advance your project swiftly and cost-effectively without compromising on quality.

Target to candidate nomination

We foster collaborations with organisations from the pharmaceutical, biotech, and academic sectors to accelerate drug discovery from target validation and hit identification to candidate nomination. Our 200-plus strong, multidisciplinary team works at a state-of-theart R&D facility near Rome where projects are carried out “under one roof” enabling rapid cycle times and close integration of the scientific teams.

World-class integrated drug discovery

More than a third of IRBM’s partnerships have been integrated projects for both small molecules and peptides, combining biology, chemistry, ADME, and in vivo studies, which profit enormously from the tightly knitted disciplines located in one facility. Staff turn over is low and many of the scientific team have worked together on drug discovery projects for more than 20 years. A few key capabilities are highlighted below.

Assay development and screening

We identify and expand high-quality hits and hit series using one or more hit-finding strategies through our wide range of biochemical/cell-based assay platforms. We carry out high-throughput screening campaigns using our diverse and highly curated small molecule collection and/or your libraries.

Phage display

We interrogate a vast number of different molecules quickly and efficiently to identify the best and most promising binders for a particular target, with our inhouse collection of high-complexity, proprietary, fullyhumanised antibody and peptide libraries. We construct custom libraries, with design, selection and screening strategies suited to your needs, based on over 20 years’ experience.

Peptide drug discovery

We discover and develop a variety of peptide drug candidates, including, but not limited to, macrocycles that incorporate multiple constraints or peptides conjugated to fatty acids, cholesterol, and polymers. IRBM is one of the leading experts in the field of peptide drug discovery - stemming from our heritage as MSD’s Peptide Research Centre of Excellence.

Biomarker identification and development

We design and implement the most successful preclinical and clinical biomarker plan for your programme, based on our deep expertise in target engagement, pharmacodynamics, and responder identification biomarkers.